Proteomics Approaches to Elucidate Oncogenic Tyrosine Kinase Signalingin Myeloid Malignancies

Publisher： Bentham Science Publishers

E-ISSN： 1873-4316|7|3|185-198

ISSN： 1389-2010

Source： Current Pharmaceutical Biotechnology, Vol.7, Iss.3, 2006-06, pp. : 185-198

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Developing Target Therapy Against Oncogenic Tyrosine Kinase in Myeloid Maliganacies

By  

Current Pharmaceutical Biotechnology, Vol. 7, Iss. 5, 2006-10 ,pp. : 331-337

Bentham Science Publishers

Access to resources Recommend Favorite

Proteomics approaches for myeloid leukemia drug discovery

By Kapoor Isha   Pal Pooja   Lochab Savita   Kanaujiya Jitendra Kumar   Trivedi Arun Kumar  

Expert Opinion on Drug Discovery, Vol. 7, Iss. 12, 2012-12 ,pp. : 1165-1175

Informa Healthcare

Access to resources Recommend Favorite

Oncogenic Signaling Pathways Activated by RON Receptor Tyrosine Kinase

By  

Current Cancer Drug Targets, Vol. 3, Iss. 1, 2003-02 ,pp. : 31-40

Bentham Science Publishers

Access to resources Recommend Favorite

Mechanisms of Clinical Resistance to Small Molecule Tyrosine Kinase Inhibitors Targeting Oncogenic Tyrosine Kinases

By Heiko van der Kuip  

American Journal of PharmacoGenomics, Vol. 5, Iss. 2, 2005-01 ,pp. : 101-112

Adis International

Access to resources Recommend Favorite

PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies

By Winer Eric S   Ingham Randall R   Castillo Jorge J  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 3, 2012-03 ,pp. : 355-361

Informa Healthcare

Access to resources Recommend Favorite